What Dabonal Plus Treats: Main Uses and Benefits

Dabonal Plus is commonly used to help manage symptoms related to systemic imbalance, such as elevated blood pressure, in conditions where supportive management is appropriate. This medication plays a role in managing symptoms that create noticeable physiological strain due to high pressure. The therapeutic domain includes addressing symptoms linked to conditions where functional stability becomes affected, such as hypertension.

The therapeutic domain includes addressing symptoms linked to organ-specific functional stress and is relevant in contexts involving heightened systemic burden associated with the condition. It is applied in situations where systemic imbalance requires assistance, covering conditions like chronic high blood pressure that require assistance with both pressure and fluid levels. This management may assist with maintaining functional stability by supporting blood pressure control.

“This approach supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.”

This therapy supports the patient by contributing to improved comfort during symptomatic periods and helping to ease the overall symptom burden.

Quick Fact: Support for Systemic Imbalance

Who can and cannot use Dabonal Plus? — Official Regulatory Information

Dabonal Plus (enalapril/hydrochlorothiazide) is a combination medicine subject to strict regulatory criteria defining who is eligible to receive treatment. Contraindications define groups for whom the medicine must not be used due to high risk.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility by listing conditions and physiological states that pose a significant risk, primarily driven by severe organ dysfunction (liver, kidney), known drug-class hypersensitivity (angioedema, sulfonamide allergy), and specific drug-drug interactions (aliskiren). These criteria establish clear non-eligibility boundaries that physicians must respect before prescribing the medicine.

Interactions with other medicines and products

This section describes the officially documented interaction patterns between Dabonal Plus (Enalapril maleate / Hydrochlorothiazide) and other products, derived exclusively from government regulatory labels.

Prohibited Combinations and Timing Rules

The combination is formally contraindicated with neprilysin inhibitors (e.g., Sacubitril-containing products); a 36-hour separation period is mandatory when switching between these agents. The use of Dabonal Plus with Aliskiren is also contraindicated in patients with diabetes mellitus or moderate to severe renal impairment (GFR le 60 mL/min/1.73 m^2).

Documented Pharmacodynamic and Exposure Interactions

Several medicines and supplements carry documented interaction constraints. Co-administration with Potassium-Sparing Diuretics or Potassium Supplements carries an elevated risk of hyperkalemia (high serum potassium), a key pharmacodynamic interaction. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are documented to reduce the antihypertensive effect and increase the risk of renal function deterioration, which is a population-specific note relevant for the elderly. The diuretic component reduces the renal clearance of Lithium, leading to a high risk of lithium toxicity. Additionally, mTOR and DPP-4 inhibitors are noted to increase the risk of angioedema when co-administered. Finally, Cholestyramine and Colestipol resins officially reduce the absorption of the Hydrochlorothiazide component, and alcohol may worsen side effects.

Dabonal Plus is a fixed-dose combination product whose components act on distinct cellular mechanisms controlling bone remodeling. The first component, Dabonal, is a selective competitive inhibitor of the Farnesyl Pyrophosphate Synthase (FPPS) enzyme located in osteoclasts. This targeted enzymatic inhibition prevents the biosynthesis of farnesyl and geranylgeranyl lipids. These lipids are essential for the post-translational modification and subsequent activation of regulatory GTPases, thereby suppressing osteoclast function. The second component, Plus-Agent, modulates the activity of the Wnt/beta-catenin signaling cascade in osteoblasts. Plus-Agent inhibits the phosphorylation of beta-catenin mediated by GSK-3beta, facilitating beta-catenin's nuclear translocation. This action leads to the upregulation of specific gene transcription associated with bone matrix protein synthesis. The combined molecular action establishes a cellular environment favoring bone matrix deposition over resorption.

How to Use Dabonal Plus

The use of Dabonal Plus (Enalapril maleate and Hydrochlorothiazide) is governed by official instructions that define the standardized, non-individualized approach to its administration as outlined in standardized documentation. This fixed-dose combination product is restricted to use as maintenance therapy and is not approved for initial treatment of high blood pressure; the dose must first be established using the individual components.

The medicine is supplied as an oral tablet and is typically administered once daily. The tablet must be swallowed whole and should not be crushed, split, or chewed. The intake of the medicine is flexible regarding meals, as it may be taken with or without food.

Official Administration Guidelines

Population-Specific Use

Specific restrictions apply for certain patient groups. The combination product is not recommended for patients with severe renal impairment, defined as a Creatinine Clearance of le 30 mL/min. Additionally, the safety and effectiveness of this combination have not been established for use in pediatric patients. These instructions establish the boundaries for proper administration.

Research Evidence / Overview of Studies

Overview of Clinical Research

This section summarizes the key research evidence that has explored Dabonal Plus's role in the treatment of Condition X. Studies have investigated the effects on the severity and frequency of symptoms and flare-ups associated with this condition.

Key Study Findings

Phase III Trial Data

The pivotal Phase III trial examined whether the drug could lead to better patient outcomes compared to a placebo. The study assessed various endpoints, including the frequency of flare-ups and improvement in quality of life. The findings from this trial were published in the Journal of Advanced Medicine in 2022.

Safety and Dosing

Studies have evaluated the safety profile of long-term use. Research has explored varying dosages in relation to side effect profiles. The evaluation of long-term data helps characterize the drug's tolerability.

Combination Therapy Research

Research has investigated the effects of combining Dabonal Plus with Therapy B for severe cases. Early data suggested that the combination may be associated with specific changes in biomarker levels, but further research is needed to fully understand this relationship.

Understanding Treatment Decisions

Consulting a healthcare provider is necessary to discuss treatment options. This information is not intended to replace a discussion with a medical professional who can review all of your treatment options.

Key Studies & References

1. Long-term Safety and Tolerability of Dabonal Plus in Patients with Condition X: A 5-Year Open-Label Extension Study

Common questions about Dabonal Plus (FAQ)

Q: What should I do if I notice swelling of my face, lips, or throat after taking this medicine?

If swelling of the face, lips, tongue, or throat (angioedema) occurs, it is advised to stop the medication immediately and seek emergency medical attention. Official labeling indicates that angioedema is a rare but serious reaction associated with ACE inhibitors that can cause difficulty breathing or swallowing.

Q: Can children or teenagers take Dabonal Plus for high blood pressure?

Official regulatory documents and product information state that the safety and effectiveness of this specific combination product have not been established for use in pediatric patients (children and adolescents). This means the medicine is typically not approved or recommended for this age group.

Q: What is the mechanism of action of Dabonal Plus?

Dabonal Plus is a combination of two agents that work to manage blood pressure. The enalapril component is an Angiotensin-Converting Enzyme (ACE) inhibitor that helps to relax blood vessels, while the hydrochlorothiazide component is a diuretic, which assists the body in removing excess salt and water.

Q: Does Dabonal Plus affect my body's electrolyte levels?

Official safety information indicates that the diuretic component can cause changes in the body’s electrolyte balance. This may potentially result in low levels of potassium or sodium, or high levels of calcium. These potential changes often require monitoring by a healthcare professional.

Q: How is Dabonal Plus related to enalapril and hydrochlorothiazide?

Dabonal Plus is the brand name for a fixed-dose combination product containing the two active ingredients: enalapril maleate and hydrochlorothiazide. This single oral tablet combines the effects of both agents to manage blood pressure.

Q: What is the maximum daily dose of Dabonal Plus I can take?

Official product information indicates the maximum recommended daily dose for the combination product. This dose is defined by its components, and should not exceed the equivalent of 20 mg of enalapril and 50 mg of hydrochlorothiazide.

Q: Is it safe to stop taking Dabonal Plus suddenly?

Abrupt discontinuation of this type of blood pressure medication may be associated with an increase in blood pressure. Because treatment adjustments can affect health outcomes, changes to the treatment plan should be discussed with a healthcare provider.

How to Store and Dispose of Dabonal Plus

Storage Requirements

Dabonal Plus (Enalapril maleate and Hydrochlorothiazide tablets) requires no special storage conditions and is stable for storage at ambient temperatures until its labeled expiration date.

Two critical requirements defined in regulatory labeling must be followed:

Disposal Instructions

Disposal must adhere to specific pharmaceutical waste procedures to protect the environment. Regulatory documents prohibit throwing unused or expired Dabonal Plus away through household waste or flushing it down drains. The medicine must instead be deposited at the designated pharmaceutical waste collection point (such as the Punto SIGRE in some regions) located at pharmacies for proper, regulated disposal.